Shionogi and Co Ltd

Trending Articles

  1. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  2. Stablepharma and AJ Vaccines to sign a distribution deal for SPVX02 AJ Vaccines will be responsible for the distribution and commercialisation of the fridge-free adult booster vaccine for tetanus and diphtheria across Europe
  3. Reckitt expands US OTC manufacturing footprint with North Carolina facility The site in Wilson will be responsible for producing Mucinex® branded tablets and liquids, which are designed as over the counter (OTC) medicines for cold and flu symptoms
  4. Modular automated flow synthesis of spirocyclic THNs from primary alkylamines Asynt and the Cresswell Group achieve advances in drug discovery scaffolds
  5. Amgen invests $1bn into new US drug manufacturing facility The site will be the CDMO's second drug substance manufacturing facility in North Carolina, and will boost its presence in the US pharmaceutical market

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Drug Delivery

Akili and Shionogi sign deal to expand digital medicine to Asia

Treatment for ADHD and autism dosed by an action video game is under review by the US FDA and has already found a distributor for Japan and Taiwan
Media

Positive Phase III results in high-risk patients expected to support FDA review process for Roche’s Xofluza

Following the recent news that Roche has announced positive top-line results from its Phase III trial for influenza drug, Xofluza, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view
Digital

Shionogi modernises product quality management in the cloud

Pharmaceutical company in Japan unifies product quality management processes across global stakeholders
Research & Development

Egalet terminates collaboration with Shionogi

Gains worldwide rights to Phase ! abuse-deterrent, extended-release hydrocodone product candidate
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
You need to be a subscriber to read this article.
Click here to find out more.

Japan funds R&D for tropical medicines for poor countries

Japanese drug manufacturers are increasing their efforts to ensure more accessible and effective medicines are brought to the developing world
Research & Development

Egalet to collaborate with Shionogi to develop abuse-deterrent oral hydrocodone opioid product candidates

Will receive upfront and milestone payments plus potential royalties on net sales
Subscribe now